SCHEMBL4127737

SCHEMBL4127737

COc1cc(C=C2SC(Nc3ccc(CC(=O)O)cc3)=NC2=O)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 13/20 0.49
MEN1 O00255 12/20 0.49
MAPT P10636 10/20 0.49
ALDH1A1 P00352 8/20 0.49
HPGD P15428 3/20 0.49
THRB P10828 1/20 0.45
MCL1 Q07820 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
LMNA P02545 3/20 0.42
POLB P06746 2/20 0.42
RECQL P46063 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KDM4E B2RXH2 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4127729 1.00 KMT2A (0.49) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4136345 0.92 KMT2A (0.51) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4131441 0.92 KMT2A (0.51) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4132695 0.86 KMT2A (0.46) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4132691 0.86 KMT2A (0.46) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4128941 0.85 MAPT (0.42) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4128939 0.85 MAPT (0.42) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4122900 0.83 MAPT (0.49) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4122898 0.83 MAPT (0.49) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4133591 0.82 ALOX5 (0.50) KMT2AMEN1MAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ KMT2A 2895/4885MEN1 4075/4885MAPT 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.